Entering text into the input field will update the search result below

OncoSec surges 20% after teaming up with Merck for late-stage TAVO/Keytruda trial

  • OncoSec Medical (NASDAQ:ONCS) has entered into a clinical trial collaboration and supply agreement with Merck (NYSE:MRK) to evaluate the combination of TAVO with Keytruda in a global late-stage trial.
  • OncoSec shares up more than 20% post market.
  • The trial will evaluate the overall survival

Recommended For You

About ONCSQ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ONCSQ--
OncoSec Medical Incorporated